The Experts below are selected from a list of 4557 Experts worldwide ranked by ideXlab platform
Tommy Fornander - One of the best experts on this subject based on the ideXlab platform.
-
adjuvant goserelin and Ovarian Preservation in chemotherapy treated patients with early breast cancer results from a randomized trial
Breast Cancer Research and Treatment, 2009Co-Authors: Asgerdur Sverrisdottir, Marianne Nystedt, H Johansson, Tommy FornanderAbstract:The purpose of this randomized study was to examine if goserelin concomitant to CMF-chemotherapy as adjuvant treatment for premenopausal breast cancer, protects the ovaries from premature failure. A total of 285 premenopausal breast cancer patients, in a randomized adjuvant trial (Zoladex in premenopausal patients (ZIPP)), were assigned to a study on Ovarian function. Node positive patients were assigned to CMF-(cyclophosphamide, methotrexate and 5-fluorouracil) chemotherapy in addition to endocrine therapy. All patients were randomly assigned to receive 2 years of goserelin, goserelin plus tamoxifen, tamoxifen alone or no endocrine treatment. We studied, if menses were affected in the treatment groups, up to 36 months after randomization. One year after completed CMF- and endocrine therapy, 36% of the women in the goserelin group reported menses, compared to 7% in the goserelin plus tamoxifen group, 13% in the tamoxifen group and 10% of the controls. Among women treated with goserelin, there was a statistically significant increase in the proportion of menstruating women, 1 year after completed treatment compared to at 24 months of treatment (P = 0.006), in contrast to all other treatment groups, who were unchanged or more often amenorrheic. In our study, there is some evidence of protective effect of goserelin on Ovarian function in CMF treated women. This effect was not observed in the combined tamoxifen and goserelin treatment.
Nicolette Warren - One of the best experts on this subject based on the ideXlab platform.
-
effect of hysterectomy with Ovarian Preservation on Ovarian function
Obstetrics & Gynecology, 2011Co-Authors: Patricia G Moorman, Evan R Myers, Joellen M Schildkraut, Edwin S Iversen, Frances Wang, Nicolette WarrenAbstract:Objective To prospectively estimate the risk for earlier Ovarian failure among women undergoing hysterectomy with Ovarian Preservation, as compared to women of similar age without hysterectomy.
Jesus Jimenez S Lopez - One of the best experts on this subject based on the ideXlab platform.
-
prophylactic salpingectomy and prophylactic salpingoophorectomy for adnexal high grade serous epithelial carcinoma a reappraisal
Surgical Oncology-oxford, 2015Co-Authors: Reyes Oliver M Perez, Javier F Magrina, Alvaro Tejerizo Garcia, Jesus Jimenez S LopezAbstract:Abstract At present, there is no effective screening of Ovarian cancer. Primary prevention may be the only strategy to decrease the mortality from Ovarian cancer, not only in women at high risk but also at low risk. Several recent studies have identified the distal fimbriae end of the fallopian tubes as primary precursor of High-grade serous carcinoma. Serous tubal intraepithelial carcinomas and occult invasive serous carcinomas have been identified in 2–17% of the fallopian tubes of BRCA1/2 positive women undergoing risk-reducing salpingo-oophorectomy. Removal of the fallopian tubes with Ovarian Preservation has been suggested as a reasonable strategy that could reduce the risk of developing Ovarian carcinoma in both low and high-risk women. It has been proposed after childbearing in women at high risk to be followed by bilateral oophorectomy at a later date. Bilateral salpingectomy is also suggested for low risk women, at the time of other benign gynaecologic surgery as a primary preventive strategy. Some studies have shown a risk reduction of Ovarian cancer in women with bilateral prophylactic salpingectomy. Current research regarding bilateral salpingoophorectomy as primary prevention approach of Ovarian cancer is reviewed here. In addition, the potential use of bilateral salpingectomy as prevention approach of Ovarian cancer is discussed.
Joohyun Nam - One of the best experts on this subject based on the ideXlab platform.
-
the impact of tumor morcellation during surgery on the outcomes of patients with apparently early low grade endometrial stromal sarcoma of the uterus
Annals of Surgical Oncology, 2011Co-Authors: Jeongyeol Park, Dae Yeon Kim, Jong Hyeok Kim, Yong Man Kim, Youngtak Kim, Joohyun NamAbstract:The purpose of this study was to evaluate the impact of tumor morcellation on the outcomes of patients with apparently early low-grade endometrial stromal sarcoma (LGESS). Outcomes were retrospectively compared between patients with apparently early LGESS who did not (group A, n = 27) or did (group B, n = 23) undergo tumor morcellation. There were no between-group differences in age, menopausal status, parity, body mass index, and preoperative presumptive diagnosis, nor were there between-group differences in tumor stage, tumor size, myometrial invasion, lymphovascular space invasion, frequency of Ovarian Preservation, adjuvant therapy, or follow-up time. More patients in group A underwent lymph node dissection (51.9 vs. 21.7%; P = 0.029). Only 1 patient in each group had distant recurrence. There were 2 patients (7.4%) in group A and 7 (31.4%) in group B who had abdominopelvic recurrence. The risk of abdominopelvic recurrence was significantly higher in group B than in group A (odds ratio [OR], 5.47; 95% confidence interval [95% CI], 1.04–29.70; P = 0.035). The 5-year disease-free survival (DFS) rates were 84% for group A and 55% for group B (P = 0.028) and the 5-year abdominopelvic DFS rates were 89 and 58% (P = 0.023), respectively. Multivariate analysis showed that tumor morcellation were significantly associated with poorer DFS (OR, 4.03; 95% CI, 1.06–15.30; P = 0.040) and abdominopelvic DFS (OR, 5.06; 95% CI, 1.02–25.04; P = 0.047). Inadvertent tumor morcellation during surgery has an adverse impact on the outcomes of patients with early LGESS.
Asgerdur Sverrisdottir - One of the best experts on this subject based on the ideXlab platform.
-
adjuvant goserelin and Ovarian Preservation in chemotherapy treated patients with early breast cancer results from a randomized trial
Breast Cancer Research and Treatment, 2009Co-Authors: Asgerdur Sverrisdottir, Marianne Nystedt, H Johansson, Tommy FornanderAbstract:The purpose of this randomized study was to examine if goserelin concomitant to CMF-chemotherapy as adjuvant treatment for premenopausal breast cancer, protects the ovaries from premature failure. A total of 285 premenopausal breast cancer patients, in a randomized adjuvant trial (Zoladex in premenopausal patients (ZIPP)), were assigned to a study on Ovarian function. Node positive patients were assigned to CMF-(cyclophosphamide, methotrexate and 5-fluorouracil) chemotherapy in addition to endocrine therapy. All patients were randomly assigned to receive 2 years of goserelin, goserelin plus tamoxifen, tamoxifen alone or no endocrine treatment. We studied, if menses were affected in the treatment groups, up to 36 months after randomization. One year after completed CMF- and endocrine therapy, 36% of the women in the goserelin group reported menses, compared to 7% in the goserelin plus tamoxifen group, 13% in the tamoxifen group and 10% of the controls. Among women treated with goserelin, there was a statistically significant increase in the proportion of menstruating women, 1 year after completed treatment compared to at 24 months of treatment (P = 0.006), in contrast to all other treatment groups, who were unchanged or more often amenorrheic. In our study, there is some evidence of protective effect of goserelin on Ovarian function in CMF treated women. This effect was not observed in the combined tamoxifen and goserelin treatment.